Ingredient in pre-clinical treatment for retinal neovascular disease targets gene associated with acute myeloid leukaemia
An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukaemia cells without harming non-leukemic blood cells.
The results, published today (19 December) in Nature Communications reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis.
Acute myeloid leukaemia (AML) is a form of blood cancer that affects people of all ages, often requiring months of intensive chemotherapy and prolonged hospital admissions. It develops in cells in the bone marrow crowding out the healthy cells, in turn leading to life-threatening infections and bleeding.
Mainstream AML treatments have remained unchanged for over 30 years, with the current treatment being chemotherapy, and the majority of people’s cancer cannot be cured. A subtype of AML, driven by rearrangements in the MLL gene has a particularly bad prognosis.
In a previous study, researchers at the Sanger Institute developed an approach, based on CRISPR gene editing technology, which helped them identify more than 400 genes as possible therapeutic targets for different subtypes of AML. One of the genes, SRPK1, was found to be essential for the growth of MLL-rearranged AML. SRPK1 is involved in a process called RNA splicing, which prepares RNA for translation into proteins, the molecules that conduct the majority of normal cellular processes, including growth and proliferation.
In a new study, Sanger Institute researchers and their collaborators set out to work out how inhibition of SRPK1 can kill AML cells and whether it has therapeutic potential in this disease. They first showed that genetic disruption of SRPK1 stopped the growth of MLL-rearranged AML cells and then went on to study the compound SPHINX31, an inhibitor of SRPK1, which was being used to develop an eye drop treatment for retinal neovascular disease – the growth of new blood vessels on the retinal surface that bleed spontaneously and cause vision loss.
The team found that the compound strongly inhibited the growth of several MLL-rearranged AML cell lines, but did not inhibit the growth of normal blood stem cells. They then transplanted patient-derived human AML cells into immunocompromised mice and treated them with the compound. Strikingly, the growth of AML cells was strongly inhibited and the mice did not show any noticeable side effects.
“We have discovered that inhibiting a key gene with a compound being developed for an eye condition can stop the growth of an aggressive form of acute myeloid leukaemia without harming healthy cells. This shows promise as a potential approach for treating this aggressive leukaemia in humans.”
Dr George Vassiliou, joint leader of the research from the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute
SRPK1 controls the splicing* of RNA in the production of new proteins. An example of a gene that is affected when SRPK1 is blocked is BRD4, a well-known gene that maintains AML. Inhibiting SRPK1 causes the main form of BRD4 to switch to another form, a change that is detrimental to AML growth.
“Our study describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML. Targeting this mechanism may be effective in other cancers where BRD4 and SRPK1 play a role, such as metastatic breast cancer.”
Dr Konstantinos Tzelepis, joint lead author from the Wellcome Sanger Institute and University of Cambridge
“When Dr Vassiliou told me that SRPK1 was required for the survival of a form of AML, I immediately wanted to work with him to find out if our inhibitors could actually stop the leukaemia cells growing. The fact that the compound worked so effectively bodes well for its potential development as a new therapy for leukaemia. It will take some time, but there is real promise for a new treatment on the horizon for patients with this aggressive cancer.”
Professor David Bates, from the University of Nottingham and co-founder of biotech company Exonate, which develops eye drops for retinal diseases
Learn more: From eye drops to potential leukaemia treatment
The Latest on: Acute myeloid leukaemia
via Google News
The Latest on: Acute myeloid leukaemia
- Fundraising underway for Scranton CNA with leukemiaon January 12, 2021 at 9:09 pm
Mia Serrian of Scranton usually is the one providing the help. For the past 11 years, Serrian has worked as a certified nursing assistant in a local nursing home ...
- Augmented RIC No Help in Transplant for AMLon January 12, 2021 at 10:33 am
A sequential augmented reduced-intensity conditioning (RIC) regimen failed to improve post-transplant outcomes for patients with high-risk acute myeloid leukemia (AML) or myelodysplasia (MDS), a ...
- Health Canada Approves ONUREG® (azacitidine tablets), First Maintenance Therapy for Patients in Remission from Acute Myeloid Leukemiaon January 12, 2021 at 4:41 am
ONUREG® has shown clinically meaningful increase in overall survival for patients MONTREAL, Jan. 12, 2021 /CNW/ - Bristol Myers Squibb Canada ...
- Venetoclax Improves Treatment Landscape for Older Patients With AMLon January 11, 2021 at 2:02 pm
Kadia, MD, associated professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the treatment options for patients with newl ...
- Strategy to reduce leukaemia treatment complicationson January 10, 2021 at 9:50 am
A study published in the New England Journal of Medicine by researchers of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center sheds light ...
- FDA Lifts Partial Hold on Trial Assessing Novel Therapy for Post-Transplant Acute Myeloid Leukemiaon January 9, 2021 at 4:03 pm
The FDA has lifted a partial clinical hold on a phase 2 trial evaluating a novel therapy in patients with acute myeloid leukemia following an allogenic stem cell transplant.
- Leukemia: New Adverse Event With PARP Inhibitors in Canceron January 7, 2021 at 10:52 am
Late toxicities in the form of myelodysplastic syndrome and acute myeloid leukemia can occur even a brief exposure to PARP inhibitors, and both are associated with a high mortality rate.
- Palliative care boosts quality of life for people with advanced leukemiaon January 7, 2021 at 7:35 am
When offered early on, palliative care improves quality of life, mood, and end-of-life care for patients with advanced acute myeloid leukemia (AML).
- APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemiaon January 7, 2021 at 6:13 am
Foster City, CA, Hangzhou, China, Gaithersburg, MD, Jan 7, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and ...
- PARP inhibitors increase risk of myelodysplastic syndrome and acute myeloid leukaemia: Lancet studyon January 4, 2021 at 9:26 am
Investigators at the Normandie University, Interdisciplinary Research Unit for Cancer Prevention and Treatment, Biology and Innovative Therapeutics for Ovarian Cancers Team, Caen, France ...
via Bing News